Expansion
Kwality Pharmaceuticals Acquires 4 Acres in Amritsar for Automated Manufacturing Hub
By News Desk ·
Key takeaways
- Kwality Pharmaceuticals acquired 4 acres of land adjacent to its existing Amritsar manufacturing unit in Punjab.
- The planned facility will have 4 injectable lines and more than 6 oral solid and ophthalmic lines, designed to EU GMP requirements including Annex 1.
- The company targets project completion by Q4 FY28, with full operations expected by Q2 FY29.
Kwality Pharmaceuticals has acquired 4 acres of land adjacent to its existing manufacturing unit in Amritsar, Punjab, to build a fully automated production hub with 4 injectable lines and more than 6 oral solid and ophthalmic lines. ScanX reported the acquisition on October 19, 2026.
Kwality's Amritsar Expansion Details
The new facility is designed to address growing demand for current products while creating capacity for future launches and bioequivalence-led opportunities, according to ScanX. The design incorporates applicable EU GMP requirements, including Annex 1, to meet international standards.
The plant will feature 4 injectable lines and over 6 lines for tablets, capsules, ophthalmic, and other oral solid dosage formulations. The expansion strengthens the company's manufacturing campus in Amritsar.
Kwality Pharmaceuticals is an Indian generic pharmaceutical manufacturer founded in 1983, producing injectables, oral solids, cephalosporins, oncology products, and biologics, and exporting to more than 70 countries through B2B distribution and government tenders, according to company records.
Kwality's Regulatory and Product Milestones
Kwality Pharmaceuticals obtained EU-GMP certification for its cephalosporin and oncology manufacturing units in 2025, enabling regulated-market commercialization in Europe, according to akta.pro company records. In 2026, the company received DIGEMID regulatory approval from Peru, opening the Latin American market for product commercialization, and launched Goserelin Acetate Implant Injection, expanding into complex depot and peptide injectable formulations beyond its existing generic portfolio.
Kwality's Recent Financial Results
Kwality Pharmaceuticals reported consolidated net sales of Rs 162.35 crore for June 2026, a 45.63% year-over-year increase from Rs 111.48 crore, Moneycontrol.com reported. The company's consolidated net profit rose 114.75% to Rs 25.62 crore for the June 2026 quarter, Business Standard reported.
Kwality Pharmaceuticals conducted a virtual investor meet on August 10, 2026, to discuss operations and future outlook without disclosing unpublished price-sensitive information, ScanX reported.
What Comes Next for Kwality's New Plant
The company targets project completion by Q4 FY28, with full operations expected to commence by Q2 FY29, according to ScanX. The company's own announcement covers the Amritsar project.